Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CDA | P32320 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.38 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16781797 | 0.86 | MAPT (0.51) | MAPTCDATYMPSLC28A1SLC28A2 | |
| SCHEMBL31685622 | 0.86 | MAPT (0.51) | MAPTCDATYMPSLC28A1SLC28A2 | |
| SCHEMBL7764746 | 0.86 | MAPT (0.51) | MAPTCDATYMPSLC28A1SLC28A2 | |
| SCHEMBL28997182 | 0.83 | TK2 (0.43) | TK2MEN1KMT2ATYMP | |
| SCHEMBL28997185 | 0.83 | TK2 (0.43) | TK2MEN1KMT2ATYMP | |
| SCHEMBL20641804 | 0.83 | TK2 (0.41) | TK2MEN1KMT2ATYMP | |
| SCHEMBL31685524 | 0.80 | P2RY2 (0.42) | TYMP | |
| SCHEMBL21980556 | 0.80 | SLC28A1 (0.46) | MEN1KMT2AMAPTCDASLC28A1 | |
| SCHEMBL666288 | 0.80 | SLC28A1 (0.46) | MEN1KMT2AMAPTCDASLC28A1 | |
| SCHEMBL22983998 | 0.79 | TK2 (0.40) | TK2MEN1KMT2ATYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | TK2 2050/4885MEN1 3452/4885KMT2A 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.